



Vivimed

For Immediate Release

July 22nd 2016

**Klar Sehen Private Limited, a wholly owned subsidiary of Vivimed
announces the sale of certain products along with associated trademarks
Total consideration for the identified products and trademarks is Rs. 730 million**

Hyderabad, India, July 22, 2016: Vivimed Labs Limited ("Vivimed" or the Company), a global integrated Pharmaceuticals company, announced today the transfer and sale of identified products along with their associated trademarks by its wholly owned subsidiary Company, Klar Sehen Private Limited ("Klar Sehen"). As part of this transaction, Klar Sehen will divest certain products within its portfolio to Ordain Healthcare Global Private Limited ("Ordain Healthcare" or the Buyer), a subsidiary of Spain based Chemo Espana S.A. The total consideration for the identified product lines is Rs. 730 million.

Further, as part of the transaction, Klar Sehen will provide contract manufacturing services for the divested products to the buyer for an agreed period of time from its two plants located at Hyderabad and Kolkata.

Commenting on the development, **Mr. Santosh Varalwar, Managing Director** said:

"This is a very important strategic development at Vivimed. As part of our strategy, the Company has exited from the branded formulations in ophthalmology and will continue to focus on CMO and US generic business. Furthermore, this transaction will also provide us enhanced financial flexibility by further reducing debt as we transition into the next phase of growth."

*** **

Analyst and Investor Enquiries

Ramesh Challa, CFO
Vivimed Labs Limited

+91 40 2717 6005
Ramesh.challa@vivimedlabs.com

Saket Somani
Churchgate Partners

+91 22 6169 5988
Vivimed@churchgatepartnersindia.com

Certified True Copy
For VIVIMED LABS LTD.

S. Jugendhar
Company Secretary

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.